Back to search results
NCT06208878

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Enrolling by Invitation
Not specifiedAges 18+Observational
CRISPR Therapeutics AG
~70 participants
Updated 2025-08-14 on ClinicalTrials.gov
What's tested:Non Interventional

At a glance

Recruiting sites
0 of 22 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment.
Measured over 15 years

Conditions

Hematologic Malignancy
Solid Malignancy

Explore related trials

Malignant neoplasm of lymphoid, hematopoietic and/or related tissueSolid Malignancy

NCT06208878

Where you'd take part

This study runs at 22 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Cedars Sinai

    Los Angeles, Californiano site contact published

  • City of Hope

    Duarte, Californiano site contact published

  • Emory

    Atlanta, Georgiano site contact published

  • MD Anderson Cancer Center

    Houston, Texasno site contact published

  • Methodist Hospital-Sarah Cannon

    San Antonio, Texasno site contact published

  • Montefiore Medical Center

    The Bronx, New Yorkno site contact published

  • MSKCC

    New York, New Yorkno site contact published

  • Oregon Health and Science University

    Portland, Oregonno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document.
Must have received CRISPR CAR T cellular therapy.

What this trial measures

  • The incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment.15 years

    The number and percentage of subjects with CRISPR CAR T cellular therapy related SAEs and AESIs will be summarized.